Pharmafile Logo
Pharmafocus logo
Advanced Search

Zurampic

Showing 6 posts of 6 posts found.

shutterstock_79370437

Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts

August 7, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Ironwood, Zurampic, gout, pharma

Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back …

News
astrazeneca_plaque

AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America

June 2, 2016
Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales

UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …

News
ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016
Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …

News
astrazeneca_plaque

AZ warns of patent losses as revenues fall

February 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic

AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …

News
2000px-food_and_drug_administration_logo

FDA approves AstraZeneca’s gout drug Zurampic

December 23, 2015
Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad

The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …

News
AZ sign

FDA backs AZ gout drug despite safety concerns

October 26, 2015
Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad

FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025